Answers are grounded in this paper and cite their sources.
The non-invasive pregnancy test (NIPT) is a screening test of cell free fetal DNA in blood samples in order to detect potential abnormalities in early pregnancy. It is offered in the Netherlands to all pregnant women since April 2023. In the default version, it tests for three chromosomal abnormalities (aneuploidies) in 21, 18 and 13. Yet, women can opt in for a genome wide test, that enlarges the test for all maternal autosomes. Prior to implementation of NIPT in the Netherlands, a large implementation trial (Trident-2) had been conducted to gather information on, among other things, the frequency of unexpected findings in the mother's autosomes, such as malignancies.
No takes yet. Share an insight, caveat, or question.
Folkert J. van Kemenade (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: